Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.02. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders | 117 | GlobeNewswire (Europe) | SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board... ► Artikel lesen | |
CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
06.01. | CytoMed Therapeutics Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
06.01. | Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor | 1 | Benzinga.com | ||
06.01. | CytoMed Therapeutics In Collaboration Deal With India's SunAct Cancer Institute | 307 | AFX News | NEW DELHI (dpa-AFX) - Singapore-based CytoMed Therapeutics Ltd. (GDTC) announced Monday that it has entered into a Business & Research Collaboration Agreement or BRCA with SunAct Cancer Institute... ► Artikel lesen | |
06.01. | CytoMed and SunAct partner for cancer immunotherapy trials | 4 | Investing.com | ||
06.01. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
28.12.24 | Kimberly-Clark expands Bengaluru GDTC, fuels digital transformation | 4 | fibre2fashion | ||
05.12.24 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
20.11.24 | CYTOMED THERAPEUTICS LIMITED: Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours ... | 5 | GlobeNewswire (USA) | ||
20.11.24 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
07.10.24 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
07.10.24 | CytoMed begins clinical trial for innovative cancer therapy | 2 | Investing.com | ||
07.10.24 | CytoMed startet klinische Studie für innovative Krebstherapie | 1 | Investing.com Deutsch | ||
07.10.24 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding ... | 203 | GlobeNewswire (Europe) | SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary... ► Artikel lesen | |
03.10.24 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank | 245 | GlobeNewswire (Europe) | SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary... ► Artikel lesen | |
30.09.24 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates | 92 | GlobeNewswire (Europe) | Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
17.07.24 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta T Cells Technology for Solid and Liquid Cancers | 164 | GlobeNewswire (Europe) | SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 49,890 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
QIAGEN | 36,910 | -0,61 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,510 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
VERA THERAPEUTICS | 23,590 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
HARMONY BIOSCIENCES | 32,530 | 0,00 % | Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts | PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million... ► Artikel lesen | |
EVOTEC | 5,905 | -3,59 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
ARVINAS | 7,180 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 14,000 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
BIONTECH | 85,20 | +0,35 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 16,600 | 0,00 % | Arcutis-Aktie steigt nach Aussetzung des Rechtsstreits | ||
SPRINGWORKS THERAPEUTICS | 46,535 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BB BIOTECH | 31,350 | -1,72 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 16,950 | 0,00 % | Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% - Here's Why | ||
AVIDITY BIOSCIENCES | 29,750 | 0,00 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 10,200 | 0,00 % | Arcturus Therapeutics Holdings Aktie: Rückschritt voraus? | Biotechnologieunternehmen meldet positive Entwicklungen bei Studien zu Mukoviszidose und OTC-Mangel während die Aktie einen erheblichen Wertverlust verzeichnet Arcturus Therapeutics Holdings Inc. (ARCT)... ► Artikel lesen |